(3-Methoxyphenyl)methanediol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (3-Methoxyphenyl)methanediol
• 化学式: C₈H₁₀O₃
• 分子量: 154.16
• InChiKey: VKIYWTOOJYLHFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Energy transfer labels with mechanically linked fluorophores
  申请人：The Scripps Research Institute

  公开号：US20020115092A1

  公开（公告）日：2002-08-22

  Mechanically linked energy transfer labels comprising at least one donor fluorophore, at least one acceptor fluorophore, and at least one support member, wherein steric interactions between the donor fluorophore(s), the acceptor fluorophore(s), and/or the support member(s) induce non-covalent association between the fluorophores and the support member(s), thereby forming a three-dimensional macromolecular structure which mechanically links the donor fluorophore(s) and the acceptor fluorophore(s). Fluorescence resonance energy transfer (FRET) occurs from donor fluorophore to acceptor fluorophore through space. No direct connectivity with covalent bonds exists between the fluorophores. Instead, mechanical barriers hold the donor/acceptor fluorophores in place during the FRET process.

  机械连接能量转移标签包括至少一个给体荧光物，至少一个受体荧光物和至少一个支撑成员，其中给体荧光物、受体荧光物和/或支撑成员之间的立体作用引起荧光物和支撑成员之间的非共价结合，从而形成一个三维大分子结构，机械地连接给体荧光物和受体荧光物。荧光共振能量转移（FRET）通过空间从给体荧光物到受体荧光物发生。荧光物之间不存在共价键的直接连接。相反，在FRET过程中，机械障碍使给体/受体荧光物保持在原位。
• [EN] N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS<br/>[FR] 3-AMINOPYRAZOLES TRICYCLIQUES N-SUBSTITUES COMME INHIBITEURS DES RECEPTEURS DU PDFG
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2003097609A1

  公开（公告）日：2003-11-27

  The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the presentinvention and to methods for treating conditions such as tumors and other cell proliferative disorders.

  本发明涉及N-取代的三环3-氨基吡唑衍生物，其作为血小板源性生长因子受体（PDGF-R）激酶的抑制剂具有用途，以及制备该衍生物的方法。本发明还涉及包含本发明化合物的制药组合物，以及用于治疗肿瘤和其他细胞增殖性疾病的方法。
• Cytotoxic Agents Comprising New Tomaymycin Derivatives
  申请人：GAUZY Laurence

  公开号：US20090036431A1

  公开（公告）日：2009-02-05

  The present invention is related to new tomaymycin derivatives, their process of preparation and their therapeutic uses.

  本发明涉及新的托马霉素衍生物，它们的制备过程及其治疗用途。
• METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS
  申请人：Transfusion Health, LLC

  公开号：US20220315895A1

  公开（公告）日：2022-10-06

  This disclosure is directed to, inter alia, methods and systems for preparing oligopotent and unipotent progenitor cells of defined lineages in culture from an expanded source of CD34+ cells, media for making the same, and therapeutic compounds and compositions comprising the same for treatment a variety of diseases included, but not limited to, hematologic disorders, immune diseases, cancers, and infectious diseases.

  本公开涉及的是从扩增的CD34+细胞来源中在培养中准备定义谱系的寡能和单能祖细胞的方法和系统，用于制备相应的培养基，以及包含相应的治疗化合物和组合物，用于治疗各种疾病，包括但不限于血液学疾病、免疫性疾病、癌症和传染性疾病。
• Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
  申请人：SANOFI

  公开号：EP2371827A1

  公开（公告）日：2011-10-05

  The present invention is related to new tomaymycin derivatives of the following formula, their process of preparation and their therapeutic uses. wherein M and L are as specified in the claims.

  本发明涉及下式的新托美霉素衍生物、其制备过程及其治疗用途。 其中 M 和 L 如权利要求中所述。